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We compared a lateral flow device to galactomannan and (133)--D-glucan assays to detect invasive
aspergillosis in an established guinea pig model of pulmonary disease. The lateral flow device became positive
earlier (day 3) than the (133)--D-glucan and galactomannan assays (day 5), with all samples positive by each
assay on day 7.
Early diagnosis of invasive aspergillosis is critical for the
initiation of appropriate antifungal therapy and may improve
outcomes in high-risk patients (2). The use of sensitive biomar-
kers, including the noninvasive assays for galactomannan and
(133)--D-glucan, also reduces the use of unnecessary anti-
fungal agents (3, 5, 6). Despite their advantages, the galacto-
mannan and the (133)--D-glucan assays are confined to lab-
oratories equipped for these tests or require samples be sent to
reference laboratories. Lateral flow technology incorporates
immunochromatographic assays into simple devices for point-
of-care diagnosis. When coupled to a monoclonal antibody
specific to an extracellular glycoprotein of Aspergillus spp., this
technology is a sensitive and specific biomarker (8). Our ob-
jective was to evaluate the time to positivity and sensitivity of
a lateral flow device in an established guinea pig model of
invasive pulmonary aspergillosis (9) and directly compare
these results to those obtained using the galactomannan and
(133)--D-glucan assays.
Immunosuppressed male Hartley guinea pigs (Charles River
Laboratories) were exposed to conidia for 1 h in an aerosol
chamber (9). Serum samples were collected on days 3, 5, and 7
postinoculation. A previously described lateral flow device was
used for the serodiagnosis of invasive aspergillosis (8). Briefly,
an immunoglobulin G (IgG) monoclonal antibody (JF5) to an
epitope on an extracellular antigen secreted constitutively dur-
ing active growth of Aspergillus was immobilized to a capture
zone on a porous nitrocellulose membrane. JF5 IgG was also
conjugated to colloidal gold particles to serve as the detection
reagent. Serum was added to a release pad containing the
antibody-gold conjugate, which bound the target antigen, and
then passed along the porous membrane and bound to JF5 IgG
monoclonal antibody immobilized in the capture zone. Test
results were available within 10 to 15 min after loading the
sample. Bound antigen-antibody-gold complexes were ob-
served as a red line with an intensity proportional to the anti-
gen concentration and were classified as negative, weakly pos-
itive, moderately positive, or strongly positive (Fig. 1A, B, C,
and D). Anti-mouse immunoglobulin immobilized to the mem-
brane in a separate zone served as an internal control.
The (133)--D-glucan assay was performed using a com-
mercially available kit (Fungitell; Associates of Cape Cod)
according to the manufacturer’s instructions. The mean rate of
change in optical density (OD) at 405 nm over time was mea-
sured using a microplate spectrophotometer (Synergy HT;
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FIG. 1. Examples of results from negative (A), weakly positive (B), moderately positive (C), and strongly positive (D) lateral flow device assays.
In the absence of the Aspergillus antigen, no complex was formed in the zone containing solid-phase JF5 antibody, and a single internal control
line was observed (A).
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Biotek Instruments). Serum galactomannan was measured us-
ing a commercially available kit (Platelia Aspergillus enzyme
immunoassay; Bio-Rad Laboratories) according to the manu-
facturer’s instructions. The OD values of each sample, positive
control, negative control, and cutoff control were measured
using a microplate spectrophotometer at 450 and 630 nm, and
the galactomannan index was calculated as the OD of each
sample divided by the mean cutoff of the control. The lateral
FIG. 2. Results from serial serum samples collected over time from the same guinea pigs with invasive aspergillosis as measured by lateral flow
technology (E), (133)--D-glucan assay (F), and galactomannan assay (f). Each line represents the biomarker results from one animal at multiple
time points. Serial samples were available for measurement of each biomarker at the multiple time points for six guinea pigs (GP 1 to 6). Symbols
for the y axis of the lateral flow device graphs: , weakly positive results; , moderately positive results; , strongly positive results.
TABLE 1. Comparison of the lateral flow device and galactomannan and (133)--D-glucan assays
Assay and result
No. of positive results/no. tested
1 h Day 3 (sensitivity) Day 5 (sensitivity) Day 7 (sensitivity) Uninfected (specificity)
Lateral flow device positive 0/5 12/25 (48%) 14/17 (82%) 6/6 (100%) 0/10 (100%)
-Glucan of 80 pg/ml 0/5 0/25 (0%) 4/17 (23%) 6/6 (100%) 2/10 (80%)
Galactomannan index of 0.5 1/5 1/25 (4%) 10/17 (59%) 6/6 (100%) 0/10 (100%)
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flow assay and the (133)--D-glucan and galactomannan as-
says were performed in separate laboratories by different in-
vestigators blinded to the results of the other.
For each biomarker, the time to positivity was defined as
the first time point at which 20% of samples became positive.
Time to positivity was plotted by Kaplan-Meier analysis, and
differences in median time at which the assays became positive
were analyzed by the log-rank test. Differences in the number of
positive samples per time point between the assays were de-
termined by Fisher’s exact test. The overall specificity of each
assay was also measured in uninfected controls. All statistical
tests were performed using Prism 5.0 (GraphPad Software,
Inc.).
The assays were negative 1 h postinoculation, prior to the
onset of invasive disease, with the exception of a galactoman-
nan test result (Table 1), which likely represented a false-
positive result, as invasive disease was not yet established (9).
Each biomarker became positive early, with more than three
samples positive for each assay by day 5 postinoculation. In
serial samples from the same animals, each biomarker contin-
ued to increase throughout the study (Fig. 2A, B, and C).
When the weakly positive lateral flow device results were con-
sidered positive, the time to positivity for this assay occurred
on day 3, which was significantly earlier than with the galacto-
mannan (day 5; P  0.03) and (133)--D-glucan (day 7; P 
0.001) assays. When the weakly positive lateral flow results
were considered negative and only the moderately and strongly
positive results as positive, the time to positivity for each bi-
omarker assay occurred at the day 5 time point.
The sensitivity of each biomarker increased throughout the
study period (Table 1). Similar to the time-to-positivity results,
when the weakly positive results were considered positive, the
sensitivity of the lateral flow device on day 3 (48%) was greater
than the galactomannan (4%; P  0.001) and (133)--D-
glucan (0%; P  0.001) assays. The sensitivity of the lateral
flow device also remained higher than the (133)--D-glucan
assay on day 5 (82% versus 23%, respectively; P  0.001) but
was not significantly different than the galactomannan assay
(59%). When the weakly positive lateral flow device results
were considered negative and only the moderately to strongly
positive results as positive, the sensitivity of this biomarker was
similar to that of the galactomannan and (133)--D-glucan
assays (35%, 59%, and 23%, respectively; P  0.05). Each
biomarker was 100% sensitive at the day 7 time point. Excel-
lent specificity was also observed for each biomarker, with only
two false positives observed in uninfected animals with the
(133)--D-glucan assay (Table 1).
Certain limitations of this study must be considered. We did
not evaluate the assays in the presence of antifungal therapy,
which can reduce the sensitivity of both the galactomannan
and (133)--D-glucan assays (4, 7). Furthermore, we did not
assess the utility of this device using other biological fluids,
such as urine or bronchial alveolar lavage fluid, against pulmo-
nary aspergillosis caused by other Aspergillus isolates, or in a
nonneutropenic model, where the pathogenesis of invasive as-
pergillosis differs from that observed in neutropenic hosts (1).
Although previous work using the lateral flow device in sam-
ples from patients with invasive aspergillosis demonstrated
good sensitivity and specificity (8), further work is needed to
establish the clinical utility of this assay. Despite these limita-
tions, this study demonstrates the utility of lateral flow tech-
nology as a rapid diagnostic tool for invasive aspergillosis and
warrants further study.
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